Alaunos Therapeutics (NASDAQ: TCRT) — Company Overview, News & Financial Data
Alaunos Therapeutics focuses on T-cell receptor therapies to target solid tumors, advancing cancer treatment options.
Alaunos Therapeutics
Alaunos Therapeutics (NASDAQ:TCRT) operates in the field of biotherapeutics, focusing on developing innovative cancer treatments. Its projects revolve around utilizing T-cell receptor (TCR) therapies to target solid tumors, an approach that represents a next step in personalized cancer treatment. The objective of Alaunos is to harness the body's own immune system to fight cancer more effectively, aiming to bring groundbreaking TCR therapies from the laboratory to patients. By pushing the boundaries of cancer treatment, Alaunos is dedicated to improving patient outcomes and quality of life. The company's work is underpinned by a commitment to scientific excellence and collaboration with leading research institutions to accelerate the development of its therapies.
Snapshot
Operations
Products and/or services of Alaunos Therapeutics
- TCR-T cell therapy platform, focusing on treatments for solid tumors with proprietary TCRs targeting shared cancer-specific mutations.
- Partnerships for clinical trial expansion, including collaborations with major pharmaceutical companies to test and develop TCR therapies.
- In-house pipeline of TCR candidates, employing a high-throughput screening process to identify and enhance TCRs targeting the most prevalent mutations in cancers.
- Manufacturing capabilities for TCR-T cell therapies, ensuring scalable and efficient production processes for clinical and commercial supply.
- Research and development in next-generation TCR engineering, aiming to improve the efficacy and safety of TCR therapies.
- Out-licensing agreements, offering access to its TCR technology for development in specific territories or for particular cancer targets.
Alaunos Therapeutics executive team
- Mr. Ferdinand GroenewaldVice President of Finance